iLite Insulin Assay Ready Cells

$1,240.00

The iLite Insulin Assay Ready Cells can be used to quantify insulin activity in human serum (without interference from factors present in human serum including IGF-1) and for quantification of the activity of neutralizing anti-Insulin antibodies. The Eagle Biosciences iLite Insulin Assay Ready Cells are for research use only.

SKU: BM3060 Categories: ,

iLite Insulin Assay Ready Cells

iLite Insulin Assay Ready Cells Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite Insulin Assay Ready Cells are intended for:

  • Quantification of Insulin
  • Determination of neutralizing antibodies against Insulin

Content: >250 µL vial of Assay Ready Cells suspended in RPMI 1640 with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium.
Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C (do not store at any other temperature) and are stable as supplied until the expiry date shown. Cells should be used within 30 min of thawing and should be diluted immediately after thawing.
For Research Use Only


Key benefits of iLite® Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (>10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Description

iLite® Insulin ARCs are avian DT-40 cells (ATCC#CRL211) which has been genetically engineered to be responsive to Insulin, resulting in the specific expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor.


Application

The iLite® Insulin ARCs can be used to quantify insulin activity in human serum (without interference from factors present in human serum including IGF-1) and for quantification of the activity of neutralizing anti-Insulin antibodies. Application Notes for the following assays are available:
• Quantification of Insulin activity (LABEL-DOC-0389)
• Determination of neutralizing antibodies against Insulin (LABELDOC-0390)


Products Related to Insulin Assay Ready Cells

Insulin ELISA Assay Kit
Insulin Ultrasensitive ELISA Kit
iLite FGF-21 Assay Ready Cells

Additional Information

Background


Insulin is a peptide hormone produced by beta cells in the pancreas to regulate the metabolism of carbohydrates and fats. Insulin is provided within the body in a constant proportion to remove excess glucose from the blood. When control of insulin levels fails, diabetes mellitus can result. As a consequence, insulin is used medically to treat some forms of diabetes mellitus.

Insulin exerts its activity by binding to a high affinity heterodimeric receptor, CD220, which possesses intrinsic tyrosine kinase activity. Binding of insulin to the insulin receptor alpha chain, results in receptor dimerization, receptor auto-phosphorylation, and signaling via the IR beta chain.

The insulin-like growth factor-1 (IGF-1) can also bind with low affinity to the IR and hence potentially interfere with an assay based on activation of the IR. Furthermore, the presence of insulin in serum samples could also interfere with the detection of neutralizing antibodies (NAbs). The iLite® Insulin Assay Ready Cells has been designed to eliminate interference from presence of insulin in serum samples, IGF-1 and IGF-2.

Manual

Product Manual


Frequently Asked Questions


Publications

References


1. American Society of Health-System Pharmacists (2009). Insulin Injection. PubMed Health. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 2012-10-12.